Harnessing monocyte dynamics for treatment of multiple sclerosis; insights from experimental model studies [0.03%]
借鉴实验模型研究揭示MS治疗新策略：调控单核细胞动态或许能治疗多发性硬化症
Aqsa Bibi,Zhenjiang Yu,Lv Cui et al.
Aqsa Bibi et al.
Monocytes are central to the innate immune system's response to infection or injury. In murine, these cells are classified into distinct subsets: classical monocytes, defined by elevated Ly6C expression (Ly6Chi), intermediate monocytes (Ly6...
M2 macrophages promote IL-10+B-cell production and alleviate asthma in mice [0.03%]
M2型巨噬细胞促进IL-10+B细胞的生成并缓解小鼠哮喘症状
Baichao Yu,Xueqi Wang,Yongkun Zheng et al.
Baichao Yu et al.
Introduction: B cells have a central regulatory role in various diseases. While macrophages are found in the disease microenvironment and interact with tissue and diverse immune cells, their relationship with B cells rema...
Abnormal glucose and lipid metabolism promotes disrupted differentiation of T and B cell subsets in Behçet's disease [0.03%]
糖脂代谢紊乱影响贝赫切特病患者T/B淋巴细胞分化异常
Minghao Li,Ping Li,Xin Wang et al.
Minghao Li et al.
Introduction: Behçet's disease (BD) is a chronic, systemic inflammatory condition characterized by recurrent immune dysregulation. Materials & methods: ...
Development and evaluation of two whole-blood flow cytometry protocols for monitoring patients treated with JAK inhibitors [0.03%]
两种用于监测接受JAK抑制剂治疗患者的全血流式细胞术方案的开发和评估
Louis Waeckel,Chloé Talon,Mathilde Barrau et al.
Louis Waeckel et al.
Introduction: The clinical efficacy of Janus kinase inhibitors (JAKinibs) is highly variable and their safety profiles are poorly understood. Methods: ...
Human challenge models for vaccine development-strengths, limitations, and expansion into endemic settings: a HIC-Vac meeting report [0.03%]
人用疫苗开发挑战模型会议报告：成就、局限及在地方病流行地区的发展展望
Helen R Wagstaffe,Stephanie Ascough,Peter J M Openshaw;HIC-Vac meeting contributors
Helen R Wagstaffe
The HIC-Vac network is a unique association of researchers focussed on the development and use of human infection challenge (HIC, otherwise known as controlled human infection models or CHIM) studies for vaccine and therapeutic development,...
Frank J Ward,Paul T Kennedy,Farah Al-Fatyan et al.
Frank J Ward et al.
Immune checkpoint inhibitor (ICI) therapies have revolutionized cancer therapy and improved patient outcomes in a range of cancers. ICIs enhance anti-tumour immunity by targeting the inhibitory checkpoint receptors CTLA-4, PD-1, PD-L1, and ...
Doreen Lau,Tim Elliott
Doreen Lau
Introduction: Antigen processing and presentation are vital processes of the adaptive immunity. These processes involve a series of intracellular and extracellular events, including the enzymology within cells during anti...
Lung immune challenge study protocol: controlled exposure to inhaled resiquimod (R848) to study mechanisms of inflammation [0.03%]
肺免疫挑战研究方案：吸入给药供体来源的雷西莫德（R848）以研究炎症机制
Akhilesh Jha,Marie Fisk,Jamie Forrester et al.
Akhilesh Jha et al.
This study aims to develop a human lung immune challenge model using inhaled Resiquimod (R848), a Toll-like receptor 7/8 agonist, to investigate inflammatory mechanisms involved in the human respiratory mucosa in health and disease. This ap...
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review [0.03%]
用于在实体肿瘤中募集T细胞的双特异性T细胞连接剂：文献回顾
Laura Dewaele,Ricardo A Fernandes
Laura Dewaele
In the past decade, T-cell-based immunotherapies have grown to become some of the most promising treatments for cancer. Following the success of immune checkpoint inhibitors, other T-cell-based therapies emerged including CAR-T cells and bi...
Delivery of IL-12 by neoantigen-reactive T cells promotes antitumor immunity in murine osteosarcoma mode [0.03%]
载有IL-12的neoantigen反应性T细胞促进小鼠骨肉瘤模型中的抗肿瘤免疫反应
Cong Tian,Xingxing Sun,Hongling Zhu et al.
Cong Tian et al.
Purpose: Despite the proven clinical benefits of cytokine therapy in cancer treatment, systemic administration of cytokines such as IL-12 is constrained by dose-limiting toxicities and short half-lives. To address these c...